Faculty mentor/PI email address
jim010@aol.com
Is your research Teaching and Learning based?
1
Keywords
Sickle Cell Vaso-Occlusive Crisis, Comparative Efficacy of Intravenous Ketamine and Lidocaine in sickle cell pain crisis, sickle cell disease
Date of Presentation
5-6-2026 12:00 AM
Poster Abstract
Sickle cell disease (SCD) is a hereditary hemoglobin disorder characterized by vaso-occlusion and recurrent acute painful crises, which are the leading cause of hospitalization in affected individuals (1,2). Opioids remain the primary treatment for vaso-occlusive crisis (VOC) pain but are associated with adverse effects, tolerance, and risk of dependence, prompting investigation into opioid-sparing adjuncts (1,2). Intravenous ketamine, an NMDA receptor antagonist, has shown modest opioid reduction in randomized and observational studies, though pain score improvements are inconsistent (3–6). Intravenous lidocaine, a sodium channel blocker, has also demonstrated potential opioid-sparing effects in retrospective cohorts with limited evidence of analgesic superiority (7–9). Direct comparative data between ketamine and lidocaine remain scarce, highlighting the need for high-quality trials.
Disciplines
Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Hemic and Lymphatic Diseases | Medicine and Health Sciences
Included in
Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Hemic and Lymphatic Diseases Commons
Comparative Efficacy of Intravenous Ketamine and Lidocaine Infusions for Pain Management in Sickle Cell Vaso-Occlusive Crisis (VOC)
Sickle cell disease (SCD) is a hereditary hemoglobin disorder characterized by vaso-occlusion and recurrent acute painful crises, which are the leading cause of hospitalization in affected individuals (1,2). Opioids remain the primary treatment for vaso-occlusive crisis (VOC) pain but are associated with adverse effects, tolerance, and risk of dependence, prompting investigation into opioid-sparing adjuncts (1,2). Intravenous ketamine, an NMDA receptor antagonist, has shown modest opioid reduction in randomized and observational studies, though pain score improvements are inconsistent (3–6). Intravenous lidocaine, a sodium channel blocker, has also demonstrated potential opioid-sparing effects in retrospective cohorts with limited evidence of analgesic superiority (7–9). Direct comparative data between ketamine and lidocaine remain scarce, highlighting the need for high-quality trials.